Skip to main content

Clinical Trials Search at Vanderbilt-Ingram Cancer Center



Phase 1b Multi-Indication Study of Anetumab Ravtansine (BAY 94-9343) in Patients with Mesothelin Expressing Advanced or Recurrent Malignancies

Multiple Cancer Types

Breast, Endocrine, Esophageal, Gastrointestinal, Lung, Non Small Cell, Pancreatic
I
Horn, Leora
NCT03102320
VICCPHI1742

Tumor-Treating Fields Therapy in Preventing Brain Tumors in Patients with Extensive-Stage Small Cell Lung Cancer

Multiple Cancer Types

This trial studies how well tumor-treating fields therapy works in preventing brain tumors in patients with small cell lung cancer that has spread to other places in the body. Tumor-treating fields therapy involves the use of the NovoTTF-200A which delivers alternating electrical fields, or tumor treating fields, through ceramic discs placed on the head. This electric force may slow and / or reverse tumor growth by disrupting the way cancer cells grow.
Lung, Small Cell
N/A
Attia, Albert
NCT03607682
VICCTHO1747

Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Primitive Neuro-ectodermal Tumors

Neuroblastoma (Pediatrics)

This phase IV trial studies how well standard chemotherapy works in treating young patients with medulloblastoma or other central nervous system primitive neuro-ectodermal tumors. Drugs used in standard chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Neuroblastoma (Pediatrics)
IV
Esbenshade, Adam
NCT02875314
VICCPED1751

Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma

Liver

This pivotal, open-label, single-arm study will evaluate the anti-cancer activity of derazantinib by Objective Response Rate (ORR) by central radiology review as per RECIST v1.1 in subjects with inoperable or advanced intrahepatic cholangiocarcinoma (iCCA) whose tumors harbor FGFR2 gene fusions (by FISH performed by the central laboratory) or FGFR2 gene mutations or amplifications (based on NGS testing performed or commissioned by the respective study center) and who received at least one prior regimen of systemic therapy. Subjects will be dosed orally once per day at 300 mg of derazantinib capsules.
Liver
II
Goff, Laura
NCT03230318
VICCGI1754

Prospective Validation of Prostate Biomarkers for Repeat Biopsy: The PRIORITY Study

Prostate

Prostate
N/A
Chang, Sam
VICCURO1734

Neuroblastoma Biology Studies

Multiple Cancer Types

Neuroblastoma (Pediatrics), Pediatrics
N/A
Pastakia, Devang
NCT00256763
CCGANBL00B1

Head and Neck Tumor Tissue Repository and Clinical Database

Head/Neck

Head/Neck
N/A
Kim, Young Jun
NCT00898638
VICCHN0356

Melanoma, Pigmented Lesion and Cutaneous Malignancy Tissue and Bio-Specimen Repository

Multiple Cancer Types

Dermatologic, Melanoma
N/A
Kauffmann, Rondi
VICCMEL0287

Novel Gastrointestinal Cancer Markers in Tissue and Biofluids

Gastrointestinal

Gastrointestinal
N/A
Beauchamp, Robert
NCT00899626
VICCGI0283

Repository for National Donor Program (NMDP) Research Blood Samples.

Hematologic

Hematologic
N/A
Kassim, Adetola
NMDPBMT0346

To learn more about any of our clinical
trials, call 1-800-811-8480 or complete
the online Self-Referral Form here: